FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 THE AVONEX CHANNEL
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week
March 2005   
April 2005   
June 2005   
July 2005   
August 2005   
September 2005   
October 2005   
November 2005   
May 2006   
June 2006   
July 2006   
October 2006   
April 2010   
May 2013   
June 2013   
July 2013   
August 2013   
July 2014   
November 2014   
January 2015   
February 2015   
April 2015   
July 2015   
January 2016   
March 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

Plegridy approved by FDA for multiple sclerosis















The U.S. Food and Drug Administration (FDA) has approved Plegridy as the new multiple sclerosis treatment by Biogen Idec.

The approval of the drug is based on phase 3 clinical trials in which the drug Plegridy (peginterferon beta-1a) was administered to 1,500 MS patients and it was observed that during the first year 12-week disease progression was reduced by 38 percent when compared to placebo.

It is the only pegylated beta interferon that is approved for being used in case of relapsing MS and is applied through a pre-filled syringe every two weeks.

The drug is now cleared from FDA and also from the European regulatory authorities.

The company already markets three other MS treatments Avonex (interferon beta-1a), Tecfidera (dimethyl fumarate) and Tysabri (natalizumab).

The company however said that it faces stiff competition in the ever evolving MS market and faces competition from various eminent pharma companies.

Currently the company said that it has no plans for an extended indication of the drug.

Story Source: The above story is based on materials provided by AUTHINTMAIL
Note: Materials may be edited for content and length

Labels: , ,